Published: 12 May 2026
Application Submitted to the Swedish Medical Products Agency – ASA.P® Approaches Clinical Phase
Auxesis Pharma can today announce that on 11 May 2026 the company submitted its application to the Swedish Medical Products Agency for clinical evaluation of ASA.P®.
The application marks one of the most important milestones so far in the company’s development and means that the product’s quality, safety and scientific design will now proceed to regulatory review ahead of planned clinical studies in humans.
The extensive application material consists of several hundred pages of documentation, studies, protocols and regulatory data.
Why is this so important?
Submitting the application is one of the most important milestones in the journey of a pharmaceutical company. This is where research, formulation, safety data and scientific documentation are brought together into a complete dossier reviewed by an independent authority.
For a company in the clinical development phase, this is one of the most value-creating steps that can be achieved.
What has been submitted?
On 11 May 2026, Auxesis Pharma submitted the application for regulatory evaluation of ASA.P® to the Swedish Medical Products Agency. The review includes:
- The product formulation and quality
- Scientific design of upcoming clinical studies
- Manufacturing process and quality control
Timeline – next steps
Last week
All clinical protocols were signed.
11 May 2026
Regulatory application submitted to the Swedish Medical Products Agency.
Before Midsummer 2026
The company expects a response from the Swedish Medical Products Agency before Midsummer 2026. An approval applies throughout all EU countries.
During 2026
All clinical patient studies will be conducted and completed.
From research to clinical reality
Auxesis Pharma is now following the development plan previously communicated by the company, where the next decisive phase is to initiate clinical studies for ASA.P®.
A regulatory approval in Sweden is particularly significant since the process takes place within the framework of the EU regulatory system for clinical trials. The decision therefore carries major relevance throughout the EU – with a single regulatory step, the opportunity opens to conduct clinical studies across the European market.
Clinical phase in collaboration with CTC in Uppsala
The clinical studies will be conducted in collaboration with CTC in Uppsala – an accredited and established company with extensive experience in clinical trials.
The studies are supervised according to EU regulatory requirements by specialist teams consisting of, among others:
- Chief physicians
- Doctors
- Nurses
- Bioanalysts
- Statisticians
- Laboratory specialists
This ensures that the studies are conducted according to the highest scientific and regulatory standards.
The participation of an experienced and accredited clinical partner such as CTC is viewed as an important quality indicator in the continued development process.
EMA SME status confirmed – fifth consecutive year
In parallel with the regulatory process, Auxesis Pharma has for the fifth consecutive year had its SME status approved by the European Medicines Agency (EMA) for 2026.
The SME status gives the company access to regulatory support, reduced fees and scientific guidance from the EMA – an important tool in the continued development towards market launch. The renewal of the status for the fifth consecutive year confirms that Auxesis Pharma fulfills EMA’s requirements as a serious and active pharmaceutical development company.
What does this mean for Auxesis – and the next steps
Validation
The regulatory submission is an independent validation of all the work invested in formulation, safety and documentation.
Market reach
One approval applies throughout the EU – one of the world’s largest pharmaceutical markets opens in a single step.
Clinical phase
With approval in place, clinical studies in humans can begin in collaboration with CTC in Uppsala.
Value creation
The transition from preclinical to clinical phase has historically been one of the most value-creating milestones for a pharmaceutical company.
This creates a strong foundation for the next step in our clinical and commercial journey – bringing Auxesis Pharma closer to the goal of delivering ASA.P® to patients throughout Europe.